Diamine derivatives as inhibitors of leukotriene A
This invention is directed to compounds of formula (I): where r, q, R, R 2 , R 3 , R 4 , R 5a , R 5b , R 5c , R 6a , R 6b , R 6c , R 7 , R 8 , and R 9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A 4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.
1. A method of treating a disease or disorder ameliorated by the inhibition of LTA 4 -h activity in a mammal, wherein the disease or disorder is selected from the group consisting of neurodegeneration in stroke, Alzheimer's disease, Parkinson's disease, encephalitis, HIV dementia, neuropathic pain, multiple sclerosis, and migraine, and wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of compound having Formula (I):
wherein:
R is the group
n 1 , n 2 , and n 3 are each independently 0 to 2;
r is 0 to 4;
q is 0 to 2;
R 1v , R 1w , R 1x , R 1y and R 1z are each independently hydrogen or fluoro;
R 2 and R 7 , together with the nitrogens to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl;
or R 2 and R 7 , together with the nitrogens to which they are attached and one of R 5a , R 5b and R 5c , form an optionally substituted 6- to 10-membered bridged N-heterocyclyl;
or R 2 and R 5a , together with the nitrogen and carbon to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl or an optionally substituted 6- to 10-membered bridged N-heterocyclyl;
or R 2 and R 5b , together with the nitrogen and carbon to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl;
R 3 is —O—, —R 12 —O—, or —O—R 12 —;
R 4 is a direct bond, or an optionally substituted straight or branched alkylene chain;
each R 5a , R 5b , R 5c , R 6a , R 6b and R 6c are each independently hydrogen, alkyl, haloalkyl or hydroxyalkyl;
or any one of R 5a and R 6a together, R 5b and R 6b together, and R 5c and R 6c together can be an oxo group;
R 7 is hydrogen, —R 13 —OR 10 , —R 13 —C(═O)R 10 , —R 13 —C(═O)OR 10 , —R 13 —C(═O)—R 13 —N(R 10 )R 11 , —R 13 —N(R 10 )C(═O)N(R 10 )R 11 , alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroarylalkyl, or optionally substituted heterocyclylalkyl;
R 8 is aralkyl optionally substituted with one or more substituents selected from the group consisting of halo, nitro, cyano, optionally substituted heteroaryl, hydroxyiminoalkyl, —R 13 —OR 10 , —R 13 —C(═O)R 10 , —R 13 —C(═O)OR 10 , —R 13 —C(═O)—R 13 —N(R 10 )R 11 , —R 13 —C(═O)N(R 10 )—R 14 —N(R 10 )R 11 , —R 13 —S(═O) t N(R 10 )R 11 (where t is 1 or 2), —R 13 —N(R 10 )R 11 , —R 13 —N(R 10 )C(═O)R 10 , —R 13 —N(R 10 )C(═O)—R 13 —N(R 10 )R 11 , —R 13 —N(R 10 )—R 13 —C(═O)OR 10 , —R 13 —N(R 10 )C(═O)—R 14 —S(═O) t N(R 10 )R 11 (where t is 1 or 2), —R 13 —N(R 10 )C(═O)—R 13 —N(R 10 )C(═O)R 10 , —R 13 —N(R 10 )C(═O)—R 13 —N(R 10 )—R 14 —N(R 10 )R 11 , —R 13 —N(R 10 )S(═O) t N(R 10 )R 11 (where t is 1 or 2), and —R 13 —O—R 14 —C(═O)OR 10 ;
each R 9 is independently —O—R 10 , alkyl, hydroxyalkyl, halo, haloalkyl, aryl or aralkyl;
each R 10 and R 11 is independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heterocyclyl, or optionally substituted heterocyclylalkyl;
or R 10 and R 11 , together with the nitrogen to which they are attached, form an optionally substituted N-heterocyclyl or an optionally substituted N-heteroaryl;
R 12 is an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain, or an optionally substituted straight or branched alkynylene chain;
each R 13 is independently a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain, or an optionally substituted straight or branched alkynylene chain; and
each R 14 is independently an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain, or an optionally substituted straight or branched alkynylene chain;
as a single stereoisomer or as a mixture of stereoisomers;
or a pharmaceutically acceptable thereof.
2. The method of claim 1 , wherein:
R 2 and R 7 , together with the nitrogens to which they are attached and one of R 5a , R 5b and R 5c , form an optionally substituted 6- to 10-membered bridged N-heterocyclyl.
3. The method according to claim 2 having the following formula (I-1):
4. The method according to claim 3 wherein:
R 4 is an optionally substituted straight or branched alkylene chain;
R 8 is aralkyl optionally substituted with one or more substituents selected from the group consisting of —R 13 —OR 10 , —R 13 —C(═O)R 10 , —R 13 —C(═O)OR 10 and —R 13 —C(═O)N(R 10 )R 11 ;
each R 9 is independently alkyl, halo or —O—R 10 ;
R 12 is an optionally substituted straight or branched alkylene chain;
each R 13 is a direct bond or an optionally substituted straight or branched alkylene chain.
5. The method according to claim 4 wherein:
r is 0;
R 4 is an optionally substituted straight or branched alkylene chain;
R 8 is benzyl substituted with one or more substituents selected from —R 13 —OR 10 and —R 13 —C(═O)OR 10 ;
R 10 is hydrogen, alkyl or optionally substituted aryl; and
R 12 is C 1-6 alkylene.
6. The method of claim 1 , wherein:
R 2 and R 7 , together with the nitrogens to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl.
7. A compound according to claim 6 having the following formula (I-2):
8. The method according to claim 6 having the following formula (I-3):
9. The method of claim 1 , wherein:
R 2 and R 5a , together with the nitrogen and carbon to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl or an optionally substituted 6- to 10-membered bridged N-heterocyclyl;
or R 2 and R 5b , together with the nitrogen and carbon to which they are attached, form an optionally substituted 5- to 7-membered N-heterocyclyl.
10. The method according to claim 9 which is of formula (I-4) or formula (I-5):
11. The method of claim 1 , wherein the disease or disorder is selected from the group consisting of neurodegeneration in stroke, Alzheimer's disease, Parkinson's disease, encephalitis, and HIV dementia.
12. The method of claim 1 , wherein the disease or disorder is neuropathic pain or migraine.
13. The method of claim 1 , wherein R 3 is —R 12 —O— or —O—R 12 —, and R 4 is an optionally substituted straight or branched C 1 -C 6 alkylene chain.
14. The method of claim 3 , wherein R 3 is —R 12 —O— or —O—R 12 —, and R 4 is an optionally substituted straight or branched C 1 -C 6 alkylene chain.
15. The method of claim 6 , wherein R 3 is —R 12 —O— or —O—R 12 —, and R 4 is an optionally substituted straight or branched C 1 -C 6 alkylene chain.
16. The method of claim 9 , wherein R 3 is —R 12 —O— or —O—R 12 , and R 4 is an optionally substituted straight or branched C 1 -C 6 alkylene chain.
17. The method of claim 1 , wherein n 1 , n 2 , and n 3 are each independently 0 to 1.
18. The method of claim 3 , wherein n 1 , n 2 , and n 3 are each independently 0 to 1.
19. The method of claim 6 , wherein n 1 , n 2 , and n 3 are each independently 0 to 1.
20. The method of claim 9 , wherein n 1 , n 2 , and n 3 are each independently 0 to 1.
21. A method of treating a disease or disorder ameliorated by the inhibition of LTA 4 -h activity in a mammal, wherein the disease or disorder is selected from the group consisting of neurodegeneration in stroke, Alzheimer's disease, Parkinson's disease, encephalitis, HIV dementia, neuropathic pain, multiple sclerosis, and migraine, and
wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of compound selected from the following:
4-[[(1S,4S)-5-[[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid;
4-[(1S,4S)-5-[[4-(2-fluoroethoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid;
4-[[(1S,4S)-5-[[4-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid;
4-[[(1S,4S)-5-[[4-(2,2,3,3,4,4,4-heptafluorobutoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid;
4-[[(1S,4S)-5-[[4-[(7,7,8,8,8-pentafluorooctyl)oxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid;
4-[(1S,4S)-5-[[4-(2,2,2-trifluoroethoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid;
4-[[(1S,4S)-5-[[4-(trifluoromethyl)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid;
4-[[(1S,4S)-5-[[4-(trifluoromethoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid;
4-[[(1S,4S)-5-[[4-(difluoromethoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid;
4-[[(1S,4S)-5-[[4-(1,1,2,2-tetrafluoroethoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid;
4-[[(1S,4S)-5-[[4-(2,2,3,4,4,4-hexafluorobutoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid;
4-[[(1S,4S)-5-[[4-(3,3,4,4,5,5,6,6,6-nonafluorohexyl)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid;
4-[[(1S,4S)-5-[[4-(3,3,4,4,4-pentafluorobutyl)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid;
4-[[(1S,4S)-5-[[4-(4,4,5,5,5-pentafluoropentyl)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid;
4-[[(1S,4S)-5-[[4-(4,4,4-trifluorobutoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid;
4-[(1S,4S)-5-[[4-(3,3,3-trifluoropropoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid;
4-[[(1S,4S)-5-[[4-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid;
methyl 4-[[(1S,4S)-5-[[4-(3,3,4,4,4-pentafluorobutyl)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoate;
methyl 2-methoxy-4-[[(1S,4S)-5-[[4-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoate;
methyl 2-methoxy-4-[[(1S,4S)-5-[[4-(2,2,3,3,4,4,4-heptafluorobutoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoate;
3-methoxy-4-[[(1S,4S)-5-[[4-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid;
4-[[(1S,4S)-5-[[4-(2,2,3,3,4,4,4-heptafluorobutoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]-3-methoxybenzoic acid;
3-methoxy-4-[[(1S,4S)-5-[[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid;
2-methoxy-4-[[(1S,4S)-5-[[4-(2,2,3,3-tetrafluoropropoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid;
2-methoxy-4-[[(1S,4S)-5-[[4-(2,2,3,3,3-pentafluoropropoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid; and
4-[[(1S,4S)-5-[[4-(2,2,3,3,4,4,4-heptafluorobutoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]-2-methoxybenzoic acid,
as a single stereoisomer or as a mixture of stereoisomers;
or a pharmaceutically acceptable salt thereof.
22. The method of claim 21 , wherein the compound is 4-[[(1S,4S)-5-[[4-(4,4,4-trifluorobutoxy)phenyl]methyl]-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl]benzoic acid as a single stereoisomer or as a mixture of stereoisomers; or a pharmaceutically acceptable salt thereof.
23. The method of claim 1 , wherein the disease or disorder is multiple sclerosis.